- Baiyunshan’s net income is reported at 2.52 billion yuan for the first half of the year.
- This represents a slight year-on-year decrease of 1.3% from 2.55 billion yuan.
- Revenue has increased by 1.9% year-on-year, totaling 41.83 billion yuan.
- The company has received three ‘buy’ recommendations from analysts.
- There are currently no ‘hold’ recommendations for the company.
- One analyst has recommended selling the company’s shares.
A look at Guangzhou Baiyunshan Pharmaceutical Holdings Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 5 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. is positioned positively for the long-term, with high scores in Value and Dividend indicating a sound financial standing and attractive returns for investors. The company’s commitment to offering value and providing dividends bodes well for its stability and potential growth in the future.
While the Growth, Resilience, and Momentum scores are not as high as Value and Dividend, they still reflect a decent outlook for Guangzhou Baiyunshan Pharmaceutical Holdings. With a solid foundation in manufacturing and selling Chinese patent medicine, as well as a diversified portfolio in Western and Chinese pharmaceutical products, the company’s resilience and growth potential remain evident for investors eyeing long-term opportunities in the healthcare sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
